Your browser version may not work well with NCBI's Web applications. More information here...
1: Int J Clin Pract. 2005 Feb;59(2):230-8.Click here to read Links

Update on treatment guidelines for acute bacterial sinusitis.

Klossek JM, Federspil P.

Jean Bernard Hospital, 86021 Poitiers, France. j.m.klossek@chu-poitiers.fr

Acute bacterial sinusitis (ABS) is a common complication of viral upper respiratory tract infections and represents a considerable social burden both in terms of diminished quality of life for the patient and the economic implications of decreased productivity and treatment costs. Several national health authorities have developed guidelines for the management of ABS, which aim to promote rational selection of anti-bacterial therapy to optimise clinical outcomes while minimising the potential for selection of anti-bacterial resistance as a result of inappropriate anti-bacterial usage. This article provides an overview of current guidelines, with particular focus on the clinical significance of variations in treatment recommendations and new treatment options, such as the ketolide telithromycin, which was recently added to a number of national treatment guidelines.

PMID: 15854202 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Telithromycin (Ketek® )

    Telithromycin is used to treat certain types of pneumonia (an infection of the lungs) that is caused by bacteria. Telithromycin is in a class of medications called ketolide antibiotics. It works by killing bacteria. Anti...

  • Source: AHFS Consumer Medication Information